Nearly half a million Americans are estimated to live with alpha-gal syndrome (AGS), a tick-borne allergy that can cause severe reactions to red meat and other mammalian products. The condition arises after a bite from the lone star tick, which introduces the alpha-gal molecule into the body, triggering an immune response in some individuals. As the prevalence of AGS increases across the United States, advocates and medical experts are calling for better labeling of food and medications to help affected individuals manage their condition.

Alpha-gal syndrome has seen a significant rise in cases, with some regions reporting a fivefold increase over recent years. In Massachusetts’ Dukes County, which includes Martha’s Vineyard—considered a local hotspot—the numbers have surged dramatically between 2023 and 2025. Medical specialists attribute this trend to the expanding habitat of the lone star tick.

The allergy is unique in its presentation. Unlike typical food allergies that cause almost immediate symptoms, AGS can provoke delayed reactions, sometimes occurring hours after exposure. Symptoms of the allergy can range from digestive problems and dizziness to severe anaphylaxis. Experts estimate that AGS ranks as the 10th most common allergy in the United States, but they believe many cases remain undiagnosed.

An obstacle for many living with AGS is the challenge of identifying safe foods and medications. The alpha-gal molecule is found not only in mammalian meat and dairy but also in animal-derived ingredients used in food additives, medications, vaccines, and even medical devices. These ingredients are often labeled under vague terms like “natural flavorings” or “thickeners,” making it difficult for patients to detect potential allergens. Furthermore, pharmaceutical labeling rules are less stringent, particularly for prescription medications, many of which contain animal-based components such as gelatin or lactose fillers.

To address these challenges, advocacy groups, including individuals like Erica Pernell, who lives with AGS, have been pushing for legislative changes. In early 2025, a bill titled the Alpha-Gal Allergen Inclusion Act was introduced in the U.S. House of Representatives, which would require food manufacturers to clearly identify alpha gal on product labels. A separate bill aims to mandate clearer ingredient labeling on pharmaceuticals that contain major food allergens. Proponents argue these measures would reduce the burden on patients who currently spend extensive time trying to determine if their medications or food are safe, sometimes with potentially life-saving consequences.

Medical professionals recognize the complexity of managing AGS. While some treatments and medications containing animal ingredients have been successfully administered under medical supervision, there are limited alternatives available. Additionally, the allergy can complicate routine medical procedures since some hospital supplies, sutures, and dental products may incorporate mammal-derived substances.

Researchers emphasize the need for greater understanding of the syndrome, noting that reactions vary widely among individuals, and not all those exposed to the alpha-gal molecule develop symptoms. Massachusetts and several other states have begun mandating case reporting to improve data collection and promote research on the condition.

However, funding constraints for medical research pose challenges. Experts have raised concerns over decreased federal research budgets in recent years, which could slow progress in understanding and addressing AGS.

As awareness grows, patients and advocates continue to press for enhanced labeling requirements and increased research funding, aiming to improve safety and quality of life for those affected by this increasingly common allergy.